You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Credo Diagnostics recently received the CE mark for the coronavirus test, which can provide results in 20 minutes.
Researchers identified Streptococcus pyogenes isolates from a lineage dubbed M1UK that are predicted to produce higher-than-usual levels of a scarlet fever-associated toxin.
The firm aims to stabilize and protect its existing molecular diagnostics business over the next 12 to 18 months, CEO Jack Kenny said.
Despite the diversity detected in Group A Streptococcus strains from more than 20 countries, investigators narrowed in on broadly shared sequences with relatively low variation.
The test detects Group A Strep in throat swab samples using the firm's rapid molecular diagnostics instrument called Revogene.
The test can detect resistance to two of the most commonly prescribed antibiotics used to treat strep throat, and could potentially be adapted for point-of-care use.
In Nature this week: protein-coding variants associated with body-fat distribution, and more.
Researchers used genomic, transcriptomic, and virulence data on thousands of Streptococcus pyogenes strains to identify features influencing infections.
Abbott said that the next-generation molecular POC assays have also been CLIA waived for use on the Abbott ID NOW instrument, formerly called Alere i.
The test, which received FDA clearance in late 2017, runs in as little as 18 minutes.
Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.
A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.
In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.
According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.